What is the debt of Passage Bio this year?
Passage Bio has a debt level of -21.71 USD this year.
Passage Bio Debt 2024
Passage Bio Debt
-21.71 USD
Ticker
PASG
ISIN
US7027121000
WKN
A2P0EQ
In 2024, Passage Bio's total debt was -21.71 USD, a -37.26% change from the -34.6 USD total debt recorded in the previous year.
Passage Bio Aktienanalyse
What does Passage Bio do?
Passage Bio Inc is a biopharmaceutical company focused on the treatment of rare genetic diseases. The company is headquartered in Pennsylvania, USA and was founded in 2018. The beginnings of Passage Bio Inc can be traced back to the work of the Penn Medicine Gene Therapy Program, which has been focusing on researching gene therapies for rare diseases for many years. In 2018, the company was finally founded to bring the research results to the market and help patients with rare diseases. Passage Bio's business model is to develop and market gene therapies based on AAV (Adeno-associated viruses). These viruses are injected into the body and are used to transport healthy genes into cells to replace defective or diseased genes. This can restore the production of missing or damaged proteins, which can contribute to symptom relief and disease cure. The company specializes in developing gene therapies for rare, monogenic diseases that are often caused by a single genetic defect. Such diseases are often difficult to treat and have no effective therapies. Therefore, gene therapies can be a promising option to help patients with these diseases. Passage Bio currently has four gene therapy candidates in its pipeline, all focusing on rare neurological diseases. The first candidate, PBGM01, aims to treat GM1 gangliosidosis, a genetic disorder that leads to impairment of the nervous system and often severe impairment of intellectual and physical development. The other candidates focus on treating diseases such as Krabbe disease, frontotemporal dementia, and Niemann-Pick disease type A. Passage Bio has also partnered with Catalent to support the manufacturing and packaging of its gene therapy products. The two companies are working together to develop a scalable production platform for gene therapy manufacturing, which will enable Passage Bio to produce and distribute therapies on a large scale. Overall, Passage Bio has the potential to change the lives of many patients with rare diseases. By developing gene therapies based on AAV technology, the company can create a promising therapy option for patients who currently have no other options available. With a dedicated team of researchers and development specialists, the company is working hard to develop new gene therapies that can contribute to the relief and cure of rare and serious diseases. Passage Bio ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding Passage Bio's Debt Structure
Passage Bio's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing Passage Bio's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to Passage Bio’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in Passage Bio’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about Passage Bio stock
What was the debt of Passage Bio compared to the previous year?
The debt of Passage Bio has increased by -37.26% compared to the previous year dropped.
What are the consequences of high debt for investors in Passage Bio?
High debt can pose a risk for investors of Passage Bio, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of Passage Bio?
Low debt means that Passage Bio has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from Passage Bio affect the company?
An increase in debt of Passage Bio can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of Passage Bio affect the company?
A reduction in debt of Passage Bio can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of Passage Bio?
Some factors that can influence the debt of Passage Bio include investments, acquisitions, operating costs, and revenue development.
Why are the debts of Passage Bio so important for investors?
The debts of Passage Bio are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can Passage Bio take to change the debt?
To change the debt, Passage Bio can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does Passage Bio pay?
Over the past 12 months, Passage Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Passage Bio is expected to pay a dividend of 0 USD.
What is the dividend yield of Passage Bio?
The current dividend yield of Passage Bio is .
When does Passage Bio pay dividends?
Passage Bio pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Passage Bio?
Passage Bio paid dividends every year for the past 0 years.
What is the dividend of Passage Bio?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Passage Bio located?
Passage Bio is assigned to the 'Health' sector.
Wann musste ich die Aktien von Passage Bio kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Passage Bio from 10/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/8/2024.
When did Passage Bio pay the last dividend?
The last dividend was paid out on 10/8/2024.
What was the dividend of Passage Bio in the year 2023?
In the year 2023, Passage Bio distributed 0 USD as dividends.
In which currency does Passage Bio pay out the dividend?
The dividends of Passage Bio are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Passage Bio
Our stock analysis for Passage Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Passage Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
